單源抗體發展背景MAb製備流程圖3.細胞株化極限稀釋（Limiteddilution）餵飼細胞陽性細胞再確認單源抗體應用實例Table1.PropertiesofmonoclonalantibodiesdirectedagainstthenonstructuralproteinσNSofARV-S1133N:NativeσNSPC:PolyclonalantibodyD:DenatureσNSNC:NormalcontrolserumV:Virus-infectedcellextractsC:Mock-infectedcellextracts1to10:ImmunoprecipitateswithMAbs1:47C,2:4A21,3:4A125,4:4A23,5:1F9,6:4B9,7:Gall,8:4A123,9:5F9,10:H1E1Competition(%)=()100%A:ODwithoutacompetitingAbB:ODwithahomologousAbn:ODwithacompetitorTable2.ResultsofcompetitivebindingassaybetweenmonoclonalantibodiestoARV-S1133nonstructuralproteinσNS1.Poly(A)-sepharose+σNS2.σNS+MAbs(1:5)3.σNS+MAbs(1:500)4.σNS+MAbs(1:5000)5.Normalserum+σNS6.σNS+anti-σNSAb7.Sepharose+σNS8.Sepharose+σNS+MAb1F9MAbcaptureELISAfordetectingAbtoARVσNSMAb1E1MAbcaptureELISA(crudeeσNSpreparation)